source Sell-Off Gets Scary–NASDAQ Futures Still Down at 1:30A EDT 3/28
Double Bottom -Double Top on XBI and enter site Testing February Lows at $87
Another Sell-Off= buy generic prednisone Tuesday Movers 3/27/18
Large Caps % Up- NONE
FBT Down 3.23%, IBB Down 2.77% to $105.12, QQQ down 3.24%, XBI down 4.27%
Mid-caps % Up -None
BIG RALLY-Monday Movers 3/26/18
FBT Up 2.83%, IBB 108.11 Up 2.68% , QQQ Up 3.72%, XBI Up 2.77%
Large Caps % Up
GILD 3.7, AMGN 3.4, VRTX 3.2, BIIB 3.1, REGN 2.93, CELG 2.58 BMY 2.16.
Mid Caps % Up
SGEN 5.14, AGIO 4.66, ALKS 4.08, INCY 3.99, ICPT 3.24, AVXS 2.2
Biotechs Busted Wiping Out Gains for 2018
Nowhere to Hide in this Nasty Market with NASDAQ Down over 5% for the Week.
Stop Reading and Analyzing-The Chart Gives the Clues.
Damage is Severe in Large Caps
We have summarized large cap performance below for 2018 YTD and for one year. The bad news started with the Abbvie (ABBV) clinical trial failure on Wednesday then biotech stocks (IBB) plummeted on Thursday, stabilized briefly Friday morning then got dumped enmasse at the close for losses of 2.5-5% for the week depending on the index.
Before last week’s downdraft biotech stocks were doing well particularly some of the hot stocks listed below. We will begin tracking some of those stocks which have led the marker until last week.
We are at the point where fundamentals and financial metrics gets cast aside until the market stabilizes.Technicals matter more. Many of the large and mid-cap charts over one year look horrific. Look for clues on valuations, clinical news and potential M&A moves. Below find some of the strong stocks before the correction.
- The XBI fared a bit better down 2.6% for the week but broke through lower rising channel.
- Only four large cap winners YTD: ABBV, BMY, GILD, VRTX.
- Celgene (CELG) hits $85, a 52 week low down 31%
- Previously hot mid-caps to watch for a bounce: AGIO, ALNY, ANAB, ARNA, ARRY, AVXS, BLUE, BPMC, EXEL, FMI, NBIX, NKTR.
- Gene editing stocks-look for recovery: CLLS, CRSP, EDIT, NTLA, SGMO.
- QQQs and XBI are still testing February lows but still up YTD.
Risk off with update on Wednesday.
|Ticker||Price||2017||Market||P/S||% Perform||% Perform|
|3/24/2018||Rev$B||Cap $B||12 mos YTD||2018 YTD|